Bausch Health Companies Inc. (BHC)
With Buyout Interest, Bausch + Lomb May Still Be Worth Interest At Current Levels
Bausch + Lomb stock has rebounded since January, but still offers value, especially with potential takeover interest and a solid balance sheet. BLCO shares trade at a reasonable premium to forward earnings, with a current ratio of 1.66, providing flexibility despite recent unprofitability. Risks include potential failure of takeover, economic downturns, inflation, and majority ownership by BHC, which could affect independent operations.
Op-ed: Here's why a sale of Bausch + Lomb could lead to a windfall for Bausch Health investors
Hedge fund managers sit on the boards of Bausch Health and Bausch + Lomb. They don't think like your typical corporate board, writes Ken Squire of 13D Monitor.
Bausch & Lomb reportedly exploring sale, shares rise
Bausch & Lomb stock surged on reports the American-Canadian eye health products firm is exploring a sale as it seeks to resolve issues related to its separation from its debt-laden parent company Bausch Health Cos Inc (NYSE:BHC). According to a Financial Times report citing people familiar with the matter, Bausch & Lomb is working with Goldman Sachs to gauge interest from potential buyers.
Bausch + Lomb's stock soars 18% on report company is considering selling itself
Eye-care company is working with Goldman Sachs on a deal that would extricate it from its indebted parent, the Financial Times reported.
Here's Why Bausch Health (BHC) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Health Canada Approves (Pr)CABTREO(TM) (clindamycin phosphate, adapalene and benzoyl peroxide) Triple-Combination Topical Treatment for Acne Vulgaris in Patients 12 Years of Age and Older
LAVAL, QC / ACCESSWIRE / September 11, 2024 / Bausch Health, Canada Inc., part of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced the approval by Health Canada of PrCABTREOTM (clindamycin phosphate, adapalene and benzoyl peroxide) Topical Gel 1.2%/0.15%/3.1%, a new triple-combination topical prescription treatment for acne vulgaris in patients 12 years of age and older.1 CABTREO is the first and only triple-combination topical treatment for acne approved by Health Canada with three mechanisms of action - an antibiotic, a retinoid and an antibacterial agent - to provide a safe and effective treatment.1 "The approval of CABTREO shows the continuing commitment of Bausch Health to bring innovative dermatology treatments to Canadians," said Amy Cairns, Vice-President, Commercial and General Manager, Canada, Bausch Health. "We are proud to offer this first triple-combination topical acne treatment to millions of Canadians who suffer from acne each year.
Bausch Health Solvency Remains A Concerns, Analyst Downgrades Stock
On Thursday, Bausch Health Companies BHC reported a second-quarter 2024 GAAP EPS of $0.03 compared to the consensus of $0.28.
Bausch Health (BHC) Q2 Earnings In Line, Xifaxan Boosts Sales
Bausch Health's (BHC) second-quarter adjusted earnings meet estimates while sales top the same, fueled by growth in Xifaxan sales.
Bausch Health Companies (BHC) Q2 2024 Earnings Call Transcript
Bausch Health Companies (NYSE:BHC ) Q2 2024 Earnings Conference Call August 1, 2024 8:00 AM ET Company Participants Thomas Appio - Chief Executive Officer John Barresi - Interim Chief Financial Officer Garen Sarafian - Investor Relations Conference Call Participants Glen Santangelo - Jefferies Mike Nedelcovych - TD Cowen Jason Gerberry - Bank of America Umer Raffat - Evercore ISI Leszek Sulewski - Truist Securities David Amsellem - Piper Sandler Michael Freeman - Raymond James Operator Greetings! Welcome to the Bausch Health Second Quarter 2024 Earnings Call.
Bausch (BHC) Reports Q2 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Bausch (BHC) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Bausch Health (BHC) Beats Q2 Earnings and Revenue Estimates
Bausch Health (BHC) came out with quarterly earnings of $0.98 per share, beating the Zacks Consensus Estimate of $0.89 per share. This compares to earnings of $0.81 per share a year ago.
Bausch Health Announces Second Quarter 2024 Results
Second quarter consolidated revenues of $2.40 billion, up 11% on a Reported and 8% on an Organic (non-GAAP)1 basis Consolidated GAAP Net Income Attributable to Bausch Health Companies Inc. of $10 million Consolidated Adjusted EBITDA Attributable to Bausch Health Companies Inc. (non-GAAP)1 of $798 million, up 10% Raising consolidated full-year Revenue and Adjusted EBITDA (non-GAAP)1 guidance LAVAL, QC / ACCESSWIRE / August 1, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health" or the "Company" or "we" or "our") today announced its second quarter 2024 financial results and other key updates from the quarter. "We continued our momentum in the second quarter, delivering our fifth consecutive quarter of year-over-year growth in revenues and adjusted EBITDA, underscoring the strength of our product and geographic footprint and reinforcing our strategy.
